Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorLEMAITRE, Florian
dc.contributor.authorGREGOIRE, Matthieu
dc.contributor.authorMONCHAUD, Caroline
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBOUCHET, Stephane
dc.contributor.authorSAINT-SALVI, Beatrice
dc.contributor.authorPOLARD, Elisabeth
dc.date.accessioned2022-06-10T08:55:36Z
dc.date.available2022-06-10T08:55:36Z
dc.date.issued2022-04-20
dc.identifier.issn1958-5578 (Electronic) 0040-5957 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/140183
dc.description.abstractEnOBJECTIVES: Nirmatrelvir in association with ritonavir (PAXLOVID™, Pfizer) is an antiviral agent targeting the 3-chymotrypsin-like cysteine protease enzyme (3C-like protease or Mpro) which is a key enzyme of the viral cycle of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This combination with a well-known pharmacokinetic enhancer leads to a high risk for drug-drug interactions in a polymedicated elected population for treatment. The aim of this work was to provide recommendations on behalf of the national French society of pharmacology (French Society of Pharmacology and Therapeutics; SFPT), by suggesting optimal and pragmatic therapeutic strategies if nirmatrelvir/ritonavir is to be given together with drugs commonly used, in order to ensure secured physicians' prescription. METHODS: Six clinical pharmacologists search the scientific literature to provide a first draft of recommendations. Thereafter, twelve other clinical pharmacologists verified the recommendations and proposed modifications. The final draft was then validated by all 18 participants. RESULTS: Five distinct recommendations were issued: i) contra-indications, ii) "PAXLOVID™ not recommended with the comedication", iii) "PAXLOVID™ possible whether the comedication is discontinued", iv) "PAXLOVID™ possible only after an expert advice" and v) "PAXLOVID™ possible without modification of the associated treatment". The final document comprises recommendations for 171 drugs/therapeutic classes aiming to secure prescription. In complex situations, clinicians are advised to contact their pharmacology department to obtain specific recommendations on the management of drug-drug interactions with nirmatrelvir/ritonavir. CONCLUSION: These recommendations intend to be a help for clinicians willing to prescribe nirmatrelvir/ritonavir and to prevent drug-drug interactions leading to adverse drug reactions or loss of efficacy. They constitute a guideline for primary care situations. Of course, some complex situations may require expert advices and here, again, clinical pharmacologists are at the forefront in providing therapeutic advice.
dc.language.isoENen_US
dc.subject.enPaxlovid
dc.subject.enAntiviral
dc.subject.enRitonavir
dc.subject.enDrug monitoring
dc.subject.enPharmacokinetics
dc.subject.enPharmacodynamics
dc.title.enManagement of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.therap.2022.03.005en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed35618549en_US
bordeaux.journalThérapieen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Th%C3%A9rapie&rft.date=2022-04-20&rft.eissn=1958-5578%20(Electronic)%200040-5957%20(Linking)&rft.issn=1958-5578%20(Electronic)%200040-5957%20(Linking)&rft.au=LEMAITRE,%20Florian&GREGOIRE,%20Matthieu&MONCHAUD,%20Caroline&BOUCHET,%20Stephane&SAINT-SALVI,%20Beatrice&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée